Santhera Pharmaceuticals

Startseite
Schweiz
Pratteln
Santhera Pharmaceuticals

Thank you for visiting the Santhera Pharmaceuticals page. This page serves as a resource for people who want to learn more about our company and work.

We are a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company that has dedicated more than a decade to researching effective medicines for rare neuromuscular and pulmonary diseases th

at currently lack treatment options. We are passionate about improving patients’ quality of life. Community Guidelines:

All users must comply with Facebook's terms of use (https://www.facebook.com/legal/terms) and these community guidelines. Please refer to your country’s guidelines for information on sharing
content. The views and opinions expressed by members of this community are not reflections of Santhera Pharmaceuticals. Santhera Pharmaceuticals does not endorse the information or opinions expressed or shared by members of this community. Santhera Pharmaceuticals expressly disclaims all liability. Content on this page may contain information related to various medical conditions, but this information is not intended to replace the advice of your doctor. You should always consult your provider for medical advice. We do not intend to censor audience postings. However, as the healthcare space is heavily governed, we can't engage in sensitive topics, discussion(s) about products - ours or other companies' - or treatment options on this page.

-If your comment contains any of the following or doesn't comply with these rules, it may be removed:

-If your posts are product related. Reporting product related adverse events or product complaints, or submitting product related medical enquiries should not be done through this forum. Guidance on reporting product
related adverse events or submitting medical enquiries is provided below;

-If your posts include profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content (including images, videos and links);

-If your posts offer health or medical advice;

-If your posts contain any personal information e.g. names of individuals, email addresses or phone numbers;

-If your posts violate another's copyright or intellectual property;

-If your posts are commercial, e.g. sell products and services, or recruit fans and followers;

-If your posts are excessively repetitive and/or disruptive to the community or are spam;

-If your posts contain proprietary, confidential, sensitive, or nonpublic information;

-If your posts don't follow Facebook's posting guidelines and Terms of Use;
Non-English language

Privacy Statements:

Please note that Facebook also has access to information you share with us through their platform. For more details please refer to the Facebook Privacy Policy. Please visit us at our website for further information about our company: http://www.santhera.com/

Safety Statements:

Reporting suspected adverse reactions after authorization of the medicinal product is important as this will allow quick identification of new safety information. Please report any suspected adverse reactions to Raxone® (idebenone) to your Health Authorities if required by the local regulations in your country as well as to the manufacturer of the product via email: [email protected], unless prohibited by the regulations.

28/08/2026

Managing DMD is a team effort, whether you’re talking about the researchers advancing treatment options behind the scenes, or the many specialists tirelessly working in hospitals and clinics every day, helping patients achieve their fullest potential.
At Santhera Pharmaceuticals we know that caregivers at home are the final - and crucial - member of this team and, together, it’s time to recognise the outstanding round-the-clock effort that lays the foundation for lifechanging care. After all, DMD is not only experienced by patients, but carers too, in every shape and size.
Want to highlight someone who goes the extra mile? Tag them with and say thank you for the role they play.

19/08/2026

Most people have never heard of Duchenne muscular dystrophy (DMD) — but for thousands of families, it shapes everyday life. DMD is a genetic condition that causes muscle damage from an early age, long before symptoms become apparent.

Recognising the early signs such as delayed motor milestones, difficulty climbing stairs or rising from the floor is important, enabling timely access to appropriate care, support, and therapeutic interventions. Some of the most common signs include:
• Gowers’ Sign: When a child ‘walks’ up with their arms to stand up from the floor.
• Delays in motor milestones, such as trouble climbing stairs, running or jumping.
• Enlarged calf muscles

👉 Save and share to help more people recognise the signs. Greater awareness means faster recognition, better care, and improved outcomes.

12/08/2026

Although the visible signs of DMD usually don’t appear until a child is between 2 and 3 years of age¹, the disease actually begins to affect the muscles long before birth². These silent changes start while the baby is still growing in the womb, signalling the start of a lifelong process.²

Recognising DMD early and securing a prompt diagnosis is vital so that families can access the right care, support, and interventions without delay.

16/07/2026

The ICNMD congress offered a valuable opportunity to connect with the neuromuscular community, exchange perspectives, and engage in discussions around ongoing developments in Duchenne muscular dystrophy.

Thank you to the colleagues, partners, and healthcare professionals we had the opportunity to engage with. We look forward to continuing these conversations beyond the congress.

17/06/2026

With the first signs appearing as soon as 2–3 years of age, early recognition of DMD can make a big difference, helping families access testing, support and care sooner. All of these can make a truly meaningful difference in childrens’ outcomes and quality of life. Because every child develops at their own pace, signs often vary. However, particular issues are more common than others. Swipe through to explore some of the common signs to look out for. Appropriate care all starts with awareness. Please share this post to help other parents and guardians recognise the signs of DMD as early as possible.

01/06/2026

Managing Duchenne muscular dystrophy (DMD) requires a delicate clinical balance. While the standard of care helps preserve muscle function and independence, managing treatment tolerability often creates complex decisions for patients and physicians. Swipe to explore the common timing, dosing, and long-term challenges of navigating DMD care. ➡️

Balancing efficacy and tolerability is essential to help optimise early and long-term treatment. Every decision makes a difference in DMD.

20/05/2026

At the International Conference on Duchenne and Becker Muscular Dystrophy that took place in Rome in early March, leading experts came together to share the latest progress shaping the future of DMD care.
From evolving therapeutic strategies to emerging innovations, the conversation is moving forward — bringing new hope to patients, families, and the entire community.
Take a look at the atmosphere and energy that brought the DMD community together 👉 https://www.youtube.com/watch?v=XL2olqFMTuM

Adresse

Hohenrainstrasse 24
Pratteln
4133

Telefon

+41619068950

Webseite

http://www.santhera.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Santhera Pharmaceuticals erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.